Proteomic Analysis of Prostate Cancer Field Effect

Abstract

We have undertaken a novel proteomic approach to identify proteins altered in both cancer and benign cells near the cancers. This is to take advantage of the field effect of the cancer, the malignancy associated changes in normal cells, to discover cancer altered protein that could be more abundant in serum or urine since they would come from both benign and cancer cells. We have started statistical evaluation of proteins comparing proteins in cancer (CaP), benign near (BN), benign distant (BD), and benign prostatitic hyperplasia (BPH) tissue areas of 7 prostates. In the evaluation of proteins found in 5 of at least 7 prostate specimens, 3 were changed in levels of expression comparing CaP vs BN (calreticulin, peptidylprolyl isomerase B, transferin), 4 comparing CaP vs BD (beta-microseminoprotein, filamin A, histone cluster 2, four and half LIM domains 1). However, 29 proteins were significantly varied in expression in CaP vs BPH comparisons. Calculations using missing value imputation is now being carried out to seek possible other biomarker candidate proteins.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Feb 01, 2011
Accession Number
ADA560531

Entities

People

  • Michael J. Wilson

Organizations

  • University of Minnesota

Tags

DTIC Thesaurus Topics

  • Albumins
  • Biological Factors
  • Cancer
  • Carrier Proteins
  • Cells
  • Chemistry
  • Enzyme Inhibitors
  • Neoplasms
  • Peptides
  • Prostate Cancer
  • Proteins
  • Proteomics
  • Tissues

Fields of Study

  • Biology

Readers

  • Molecular Biology and Genetics
  • Oncology and Biomarker-Based Cancer Detection.
  • Regression Analysis.

Technology Areas

  • Biotechnology